Mapmygenome launches Genomepatri Immunity report

Mapmygenome, a personal genomics solutions company, has launched Genomepatri Immunity, a report which contains genetic risk factors for immune system diseases and some lifestyle diseases such as diabetes, heart disease and other co-morbidities.

The report also covers how we respond to drugs that may be used during treatment.

“The report includes a person’s genetic response to a variety of drugs including anti-virals and anti-fungals, and levels of vitamins and minerals,” Anu Acharya, CEO, Mapmygenome, said.

“This is not a diagnostic test but we see a tremendous potential in prevention, early screening, and improving patient outcomes,” she added.

Stating that a good immune response is a key in defeating COVID-19, she said the Genomepatri Immunity report will help people fight COVID-19 and other diseases better.